Frontlight ResearchEarly access
Taking people in United StatesPhase 2
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
Key facts
- Who runs it
- Frantz Viral Therapeutics, LLC
- Where
- Cleveland, Fort Myers, Indianapolis, and Mayfield Heights, United StatesSee the 5 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 27 people, planned
- Started
- 6 Dec 2023
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Artesunate ointment
- Placebo ointment
- Record updated
- 14 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Adult women age ≥ 18 years
- Capable of informed consent
- Able to collaborate with planned follow-up (transportation, compliance history, etc)
- Biopsy diagnosis of high-grade vulvar dysplasia (VIN2, VIN3, VIN2/3, HSIL), including both new and recurrent disease. A biopsy diagnosis of vulvar high-grade squamous intraepithelial lesion within the previous 3 months which was not excised or otherwise treated may be accepted for study entry
- Positive HPV test at study entry (any genotype)
- Women of childbearing potential agree to use birth control during the dosing phase (through week 8)
- Laboratory values at Screening of:; Serum alanine transaminase (SGPT/ALT) < 5 x upper limit of normal (ULN); Serum aspartate transaminase (SGOT/AST) < 5 x ULN; Serum Bilirubin (total) < 2.5 x ULN; Serum Creatinine ≤ 1.5 x ULN
- Weight ≥ 50kg
Who cannot take part
- Concurrent anal, vulvar, or cervical cancer
- Currently receiving systemic chemotherapy or radiation therapy for another cancer
- Concomitant use of Efavirenz for HIV antiretroviral treatment
- Concomitant use of strong UGT inhibitors
- Concomitant use of imiquimod, cidofovir, or 5-fluorouracil (5-FU) for the duration of the study
- Concurrent dermatological conditions affecting the vulva (e.g., herpetic lesion, Crohn's disease, hidradenitis suppurativa) or vulvar dermatoses (e.g., lichen sclerosis or planus, atopic dermatitis, genital atrophy)
- Concurrent treatment with systemic corticosteroids
- Participants infected with HIV-1 if not on a stable, suppressive antiretroviral therapy (ART) regimen
- HIV-positive participants with a CD4 count < 200
- Pregnant and nursing women
- Unwillingness to undergo an excisional procedure at week 18 to either remove HSIL lesions, or to document histologic regression at a site where HSIL was present at study entry
This trial is currently available in United States.
- Cleveland Clinic Fairview HospitalCleveland, United StatesContact: Donna WhiteTaking people
- Cleveland Clinic FoundationCleveland, United StatesContact: Donna WhiteTaking people
- Florida Gynecologic OncologyFort Myers, United StatesContact: Edward C. Grendys, MD FACOG, FACSTaking people
- Ascension St. VincentIndianapolis, United StatesContact: Sarah Goodrich, MDTaking people
- Hillcrest HospitalMayfield Heights, United StatesContact: Donna WhiteTaking people
About the trial
What the trial wants to find out
This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2/3).
The 2 groups in the trial
- Artesunate ointmentExisting treatment, for comparison
Artesunate formulated as topical ointment, 40% Four 5-day cycles of artesunate ointment every 2 weeks
- Placebo ointmentPlacebo, for comparison
Placebo ointment Four 5-day cycles of placebo ointment every 2 weeks
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)
- Record updated
- 14 August 2025